Asset Management One Co. Ltd. Purchases 1,213 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Asset Management One Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,476 shares of the biopharmaceutical company’s stock after purchasing an additional 1,213 shares during the period. Asset Management One Co. Ltd. owned about 0.05% of Regeneron Pharmaceuticals worth $59,370,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Vanguard Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the last quarter. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after buying an additional 59,769 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,097.25.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $1.84 during mid-day trading on Monday, reaching $845.44. The company had a trading volume of 13,466 shares, compared to its average volume of 515,277. The company’s 50 day simple moving average is $1,058.43 and its 200 day simple moving average is $1,040.85. The company has a market capitalization of $93.20 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 2.88 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.62 and a current ratio of 5.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business earned $8.79 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.